A retrospective study for efficacy of low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma who progressed after anti-PD-1 monotherapy
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Ipilimumab (Primary) ; Immunotherapies
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 10 Feb 2022 New trial record